This article is part of our ongoing series exploring key tax considerations across the biotech lifecycle—from funding through exit.

For biopharma companies, the path to liquidity is rarely linear. As assets mature and strategic priorities evolve, leadership teams often face a critical decision: pursue a full company sale, monetize a specific asset, or extract incremental value by dividing more mature assets from those still being explored in pre-clinical studies. While the commercial and strategic considerations are front of mind, the tax implications of each path can materially affect value realization for both the company and its stakeholders.

Why the Exit Structure Matters

At a high level, different exit structures can produce significantly different tax results. A taxable sale, for example, may accelerate gain recognition at both the corporate and shareholder levels, depending on whether the transaction is structured as an asset or stock sale. By contrast, certain spin-off transactions may qualify for tax-free treatment under section 355, preserving value by deferring tax—provided the required conditions are satisfied.

However, these outcomes are highly dependent on structure. Alternative structures that achieve the same commercial and business objectives can be viewed differently for tax purposes and yield materially different results. For biopharma companies that have invested heavily in research and development, the ability to preserve tax attributes or defer gain can meaningfully impact overall proceeds.

Asset Sale vs. Stock Sale Considerations

In a full company sale, one of the first tax questions is whether the buyer will acquire assets or stock. Buyers in the biopharma sector often prefer asset acquisitions, which can provide a step-up in the tax basis of acquired intangible assets, including intellectual property. This may allow the buyer to amortize that basis over time, improving after-tax returns.

For sellers, however, asset sales can be less favorable. Gain is recognized at the corporate level, and a second level of tax may apply when proceeds are distributed to shareholders. A stock sale, by contrast, generally results in a single level of tax at the shareholder level and may allow qualifying investors to benefit from favorable capital gains treatment, including potential Qualified Small Business Stock (QSBS) benefits if the stock and issuer satisfy the detailed requirements of section 1202.

Where buyer and seller preferences diverge, structuring solutions and tax attribute utilization may help bridge the gap, but each introduces additional complexity and is fact-dependent, meaning that it must be carefully evaluated from a tax perspective.

Spin-Offs as a Strategic Alternative

Spin-offs can offer a compelling alternative where a company seeks to separate a business line or monetize a specific asset while preserving upside. If structured as a taxable spin-off, then the transaction tax consequences may be palatable if the spun-off asset has lower current value. A taxable spin-off will therefore allow the shareholders to retain and unlock the value of a less mature asset, while facilitating the sale of a more mature asset.

Only recently has the IRS begun sanctioning tax-free spin-offs under section 355 in the biopharma space. This is because the requirements for tax-free treatment are stringent. Companies must demonstrate, among other factors, that both the parent and the spun-off entity are engaged in an active trade or business, and that the transaction is not principally a device for distributing earnings and profits. In the biopharma context—where assets may still be pre-revenue or heavily concentrated in a single therapeutic program—the active trade or business requirements can present challenges.

Additionally, a tax-free spin-off is not optimal where an exit of either business is envisioned. That is because subsequent transactions involving either entity or asset, following the spin-off, tend to cause the spin-off itself to be taxable if the subsequent exit is not carefully considered and structured.

Tax Attributes and Transaction Timing

Another key consideration is the treatment of existing tax attributes. Biopharma companies often carry significant net operating losses (NOLs) generated through years of research and development. These attributes can provide meaningful future tax shields but may be limited or reduced in value following a change in ownership under section 382.

As a result, all prior share issuances and rounds of financing should be evaluated in advance of exit planning, as such analysis is a way to unlock value for a potential buyer, resulting in incremental transaction proceeds.

Aligning Tax Strategy with Business Objectives

Ultimately, there is no one-size-fits-all answer to an exit. The optimal path depends on a range of factors, including shareholder composition, investor holding periods, asset maturity, and strategic, commercial, and business priorities.

What remains consistent, however, is the importance of early and integrated tax planning. Tax should not be evaluated as a secondary consideration once deal terms are set. Instead, it should be embedded into the transaction strategy from the outset to ensure alignment between structure, economics, and long-term objectives.

How We Help

WilliamsMarston advises biopharma companies and their investors through complex transaction decisions, helping evaluate the tax implications of exit strategies, asset monetization, and corporate separations. If you are assessing strategic alternatives, we would welcome the opportunity to help you navigate the tax considerations and identify opportunities to maximize after-tax value.